SCHEMBL7104404

SCHEMBL7104404

Nc1ccc([C@H](N)CC(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
POLB P06746 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
ANPEP P15144 1/20 0.44
KMT2A Q03164 3/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 3/20 0.43
MEN1 O00255 2/20 0.43
CYP2D6 P10635 2/20 0.43
GABBR2 O75899 4/20 0.42
GABBR1 Q9UBS5 4/20 0.42
LMNA P02545 2/20 0.42
CYP3A4 P08684 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
NFKB1 P19838 1/20 0.42
DRD3 P35462 1/20 0.42
BLM P54132 1/20 0.42
CYP1A2 P05177 1/20 0.42
THRB P10828 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303463 1.00 SMN1; SMN2 (0.54) SMN1; SMN2POLBTDP1ANPEPKMT2A
SCHEMBL6965546 0.86 FFAR1 (0.50) SMN1; SMN2POLBANPEPKMT2ACYP2C9
SCHEMBL284828 0.83 KMT2A (0.46) SMN1; SMN2TDP1ANPEPKMT2ACYP2C9
SCHEMBL2765505 0.83 KMT2A (0.46) SMN1; SMN2TDP1ANPEPKMT2ACYP2C9
SCHEMBL3554163 0.83 KMT2A (0.46) SMN1; SMN2TDP1ANPEPKMT2ACYP2C9
SCHEMBL288753 0.83 GABBR2 (0.59) SMN1; SMN2KMT2ACYP2C19CYP2D6GABBR2
SCHEMBL123765 0.83 GABBR2 (0.59) SMN1; SMN2KMT2ACYP2C19CYP2D6GABBR2
SCHEMBL59840 0.83 GABBR2 (0.59) SMN1; SMN2KMT2ACYP2C19CYP2D6GABBR2
SCHEMBL1138613 0.82 FFAR1 (0.50) SMN1; SMN2POLBANPEPKMT2ACYP2C9
SCHEMBL2764337 0.82 FFAR1 (0.49) SMN1; SMN2ANPEPKMT2ACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162799-A1 Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents CELLTECH R&D LIMITED (GB) 2003-08-28 US disclosed
US-6518283-B1 To modify integrin function in such a way as to beneficially modulate cell adhesion CELLTECH R&D LIMITED (GB) 2003-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162799-A1 Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents ICAM1, VCAM1, CCR1 SMN1; SMN2 2700/4885POLB 1466/4885TDP1 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.